Phase i trial of active specific immunotherapy with autologous dendritic cells pulsed with autologous irradiated tumor stem cells in hepatitis B-positive patients with hepatocellular carcinoma

Journal of Surgical Oncology

Volumn 111, Issue 7, 2015, Pages 862-867

  Wang, Xiaojin ^a   Bayer, Michael E ^b   Chen, Xiaosong ^c   Fredrickson, Craig ^b   Cornforth, Andrew N ^b   Liang, Greg ^b   Cannon, Jessica ^b   He, Jia ^d   Fu, Qingchun ^a   Liu, Jia ^e   Nistor, Gabriel I ^b   Cao, Wei ^e   Chen, Chengwei ^a   Dillman, Robert O ^b  

^a Army of China   (China)

^b Caladrius Biosciences   (United States)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

^e Cellular Biomedicine Group   (China)

Author keywords

dendritic cell vaccine; hepatitis B; hepatocellular carcinoma; therapeutic cancer vaccines; tumor stem cells

Indexed keywords

CANCER VACCINE; CARBOPLATIN; DENDRITIC CELL VACCINE; EPIRUBICIN; HEPATITIS B ANTIGEN; THERAPEUTIC CANCER VACCINE; UNCLASSIFIED DRUG; VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SIZE; CANCER STEM CELL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; COCULTURE; DENDRITIC CELL; FEMALE; GOOD MANUFACTURING PRACTICE; HEPATITIS B; HUMAN; HUMAN CELL; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; IRRADIATION; LEUKAPHERESIS; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LIVER RESECTION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; AUTOTRANSPLANTATION; CANCER STAGING; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; FOLLOW UP; HEPATITIS B VIRUS; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; LIVER NEOPLASMS; MIDDLE AGED; PROGNOSIS; TRANSPLANTATION; VIROLOGY;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELLS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOTHERAPY; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PROGNOSIS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84928827745     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23897     Document Type: Article

References (43)

1. El-Serag HB,: Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127.
2. Fattovich G, Stroffolini T, Zagni I, et al.: Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004; 127: S35-S50.
3. Yang HI, Lu SN, Liaw YF, et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174.
4. Lok AS, Seeff LB, Morgan TR, et al.: Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148.
5. Ascha MS, Hanouneh IA, Lopez R, et al.: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-1978.
6. Siegel R, Ma J, Zou Z, et al.: Cancer statistics. CA Cancer J Clin 2014; 64: 9-29.
7. Child CG, Turcotte JG. Surgery and portal hypertension. In: The liver and portal hypertension. CG Child (ed). Philadephia: Saunders 1964:50-64.
8. Pugh RN, Murray-Lyon IM, Dawson JL, et al.: Transection of the oesophagus for bleeding oesophageal varices. Brit J Surg 1973; 60: 646-649.
9. Martin AP, Bartels M, Hauss J, et al.: Overview of the MELD score and the UNOS adult liver allocation system. Transplant Proc 2007; 39: 3169-3174.
10. Okuda K, Ohtsuki T, Obata H, et al.: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985; 56: 918-928.
11. Chevret S, Trinchet JC, Mathieu D, et al.: A new prognostic classification for predicting survival of patients with hepatocellular carcinoma: Group d'Etude et de Traitment du Carcinome Hepatocellulaire. J Hepatol 1999; 31: 133-141.
12. Llovet JM, Bru C, Bruix J,: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-338.
13. CLIP. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma-The Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 2000;31:840-845.
14. Leung TW, Tang AM, Zee B, et al.: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: A study based on 926 patients. Cancer 2002; 94: 1760-1769.
15. Kudo M, Chung H, Haji S, et al.: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004; 1396-1405.
16. Cillo U, Vitale A, Grigoletto F, et al.: Prospective validation of the Barecelona clinic Liver Cancer staging system. J Hepatol 2006; 44: 723-731.
17. Bruix J, Sherman M,: Management of hepatocellular carcinoma. Hepatol 2005; 42: 1208-1236.
18. Singal AG, Marrero JA,: Recent advances in the treatment of hepatocellular carcinoma. Curr Opin Gastroenterol 2010; 26: 189-195.
19. Subramaniam S, Kelley R, Venook AP,: A review of hepatocellular carcinoma (HCC) staging systems. Chin Clin Oncol 2013; 2: 33-44.
20. Zhang H, Yang T,: Staging Systems for Hepatocellular Carcinoma. Journal of Tumor 2013; 18: 20-23.
21. Hepatocellular Carcinoma Version 2.201.3. In NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®).
22. Ferenci P, Fried M, Labrecque D, et al.: World Gastroenterology Organisation guideline. Hepatocellular carcinoma (HCC): A global perspective. J Gastrointestin Liver Dis 2010; 19: 311-317.
23. Kianmanesh R, Regimbeau JM, Belghiti J,: Selective approach to major hepatic resection for hepatocellular carcinoma in chronic liver disease. Surg Oncol Clin N Am 2003; 12: 51-63.
24. Vauthey JN, Riberto D, Abdalla EK, et al.: Outcomes of liver transplantation in 490 patients with hepatocellular carcinoma: Validation of a uniform staging after surgical treatment. J Am Coll Surg 2007; 204: 1016-1027.
25. Mazzaferro V, Chun YS, Poon RT, et al.: Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 1001-1007.
26. Wang JH, Changchien CS, Hu TH, et al.: The efficacy of treatment schedules according to Barcelona Clinic Liver Cancer staging for hepatocellular carcinoma-survival analysis of 3892 patients. Eur J Cancer 44 2008; 1000-1006.
27. Abdalla EK, Denys A, Hasegawa K, et al.: Treatment of large and advanced hepatocellular carcinoma. Ann Surg Oncol 2008; 15: 979-985.
28. Truty MJ, Vauthey JN,: Surgical resection of high-risk hepatocellular carcinoma: Patient selection, preoperative considerations, and operative technique. Ann Surg Oncol 2010; 17: 1219-1225.
29. Llovet JM, Bisceglie AM, Bruix J, et al.: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.
30. Llovet JM, Rial MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment inpatients with unresectable hepatocellular carcinoma: A randomized controlled trial. Lancet 2002; 359: 1734-1739.
31. Lo CM, Ngan H, Tso WK, et al.: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-1171.
32. Morse MA, Hanks BA, Suhocki P, et al.: Improved time to progression for transarterial chemoembolization compared with transarterial embolization for patients with unresectable hepatocellular carcinoma. Clin Colorectal Cancer 2012; 11: 185-190.
33. Llovet JM, Ricci S, Mazzaferro V, et al.: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390.
34. Cheng YK, Kang AL, Chen Z, et al.: Efficacy and safety of sorafenib in patients win the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
35. Pawlik TM, Reyes DK, Cosgrove D, et al.: Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 3860-3867.
36. Tan A, Auicejo F, Kim R,: Is there a role for adjuvant treatment after hepatic resection for hepatocellular carcinoma. Oncology 2010; 78: 161-171.
37. Dillman RO, Cornforth AN, Nistor G,: Cancer stem cell antigen-based vaccines: The preferred strategy for active specific immunotherapy of metastatic melanoma. Expert Opin Biol Ther 2013; 13: 643-656.
38. Dillman RO, Selvan SR, Schiltz PM, et al.: Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific anti-tumor vaccines in patients with metastatic melanoma: Final Report. Cancer Biother Radiopharm 2009; 24: 311-319.
39. Dillman RO, Cornforth AN, DePriest C, et al.: Tumor stem cell antigens as consolidative active specific immunotherapy: A randomized phase II trial of dendritic cells versus tumor cells in patients with metastatic melanoma. J Immunother 2012; 35: 641-649.
40. Dillman RO, Nayak SK, Beutel L,: Establishing in vitro cultures of autologous tumor cells for use in active specific immunotherapy. J Immunother 1993; 14: 65-69.
41. Dillman RO, Beutel LD, Barth NM, et al.: Irradiated cells from autologous tumor cell lines as patient-specific vaccine therapy in 125 patients with metastatic cancer: Induction of delayed-type hypersensitivity to autologous tumor is associated with improved survival. Cancer Biother Radiopharm 2002; 17: 51-66.
42. Selvan SR, Carbonell DJ, Fowler AW, et al.: Establishment of stable cell lines for personalized melanoma cell vaccine. Melanoma Res 2010; 20: 280-292.
43. O.E. Rahma, E. Gammoh, R.M. Simon, et al.: Is the "3 + 3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design. Clin Cancer Res 20 2014; 4758-4767.